ARCT

NASDAQ 已收盘

Arcturus Therapeutics Holdings

15.84 USD
+0.55+3.60%
盘后 8.02 0.00%
2026-09-15
市值
$443.40M
市盈率
EPS
-3.33
股息率
52 周区间
5.50 – 24.17
成交量
556.08K
Beta
2.48
目标价
22.30
52W 低 5.5052W 高 24.17
价格走势

公司简介

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In additi...